Sanofi India Limited · NSE:SANOFI
Sanofi India — Investor Presentation (May 2023)
26 slides from Sanofi India's investor presentation, May 11, 2023
Slide 1: Outcome of Investor / Analysts Call cover letter
11th May 2023 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor Dalal Street, Mumbai - 400 001 Plot No. C/1, G Block Scrip Code: 500674 Bandra-Kurla Complex, Bandra East Mumbai - 400 050 Symbol: SANOFI Sub: Outcom
Slide 2: Investor Presentation May 2023
Investor Presentation May 2023
Slide 3: Disclaimer
Disclaimer This Release / Communication, except for the historical information, may contain statements, including the words or phrases such as expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should and similar expressions or
Slide 4: Sanofi India Limited, Case for Change, Transaction Overview, Appendix
1 Sanofi India Limited 2 Case for Change 3 Transaction Overview 4 Appendix 2
Slide 5: Sanofi India Limited
01 Sanofi India Limited
Slide 6: Sanofi is strongly committed to a healthier India
Confidential - Sensitive Sanofi is strongly committed to a healthier India Long history with over 67 years of Superior quality and compliance track record backed by presence in India robust distribution presence across India Top 4 1 pharma MNC GMP compliant manufacturing site ~INR 26.2 bn 2022 Net s
Slide 7: Strong position driven by leading brands
Confidential - Sensitive Strong position driven by leading brands General Medicines Brands Consumer Healthcare Brands #1 #5 #1 #5 Diabetes(1) Diabetes Allergy Physical Wellness #1 #7 #6 #3 CVS Neuro / CNS Pain Allergy # Brand rank Source – IQVIA MAT March 23 (1) Represents Glargine market rank 5
Slide 8: Created significant long-term value for our shareholders
Confidential - Sensitive Created significant long-term value for our shareholders Since 2010, Sanofi India delivered returns of 12.2% pa... …including significant amount of dividends (including dividends) (Dividend payout as % of PAT) Normal dividend payout increases on account of efficiency in oper
Slide 9: Case for Change
02 Case for Change
Slide 10: India for India first quarters, positive signs
India for India first quarters, positive signs Q4 Ø PBT +22% vs YA (excl exceptional items) operating efficiencies brought in by 22 IFI Ø Structure review completed with impact limited to Q4 and Q1 Ø One of the best quarters for Sanofi India Ø Signals that focus in terms of profitability on key cate
Slide 11: India for India strategy requires different approach to both businesses
Confidential - Sensitive India for India strategy requires different approach to both businesses General Medicines and Consumer Healthcare increasingly have unique and differentiated business models Products with therapeutic benefit Brands to fulfil consumer needs Scientific HCP engagement Consumer
Slide 12: We can maximize Sanofi India's India for India potential
Give each business segment specific capabilities We can maximize Sanofi India’s Remove unnecessary India for India intertwined processes potential Fully align businesses with global group structure 10
Slide 13: Sanofi India Limited to unlock value with dedicated pharma & consumer healthcare businesses
Confidential - Sensitive Press release May 10th 2023 Sanofi India Limited to unlock value with dedicated pharma & consumer healthcare businesses This decision to demerge will accelerate growth for both its pharma and consumer healthcare (CHC) businesses in India 11
Slide 14: Global activity to leverage accelerating growth in CHC
Confidential - Sensitive Global activity to leverage accelerating growth in CHC Pharma and Consumer companies The $158bn CHC market Future growth acceleration supported are increasingly focusing on CHC growing to $203bn in 2027 by multiple structural drivers Heightened and increasing consumer focus
Slide 15: Sanofi CHC India can tag on to proven Sanofi CHC global acceleration
Confidential - Sensitive Sanofi CHC India can tag on to proven Sanofi CHC global acceleration CHC January 2015 2017 Today 2020 2x higher CHC Standalone growth vs. CHC BU CHC Platform All CHC entities are fully Announced worldwide created set up autonomous market CHLOE project +4% YoY India is a key
Slide 16: Sanofi's India CHC will benefit from global COEs and local agility
Confidential - Sensitive Sanofi’s India CHC will benefit from global COEs and local agility CHC Sanofi Consumer Healthcare Global Consumer Healthcare Business Unit Local entity Marketing-> Share global best practices Agility and autonomy for local implementation of strategies Innovation-> Launch of
Slide 17: Transaction Overview
03 Transaction Overview
Slide 18: Corporate structure – expected to close by mid 2024
Confidential - Sensitive Corporate structure – expected to close by mid 2024 Current Structure Proposed Structure Sanofi Public Sanofi Public Sanofi Public 60.4% 39.6% 60.4% 39.6% 60.4% 39.6% SIL Sanofi Consumer SIL (General Medicines Healthcare business) (Demerged entity) Listed co Listed Company L
Slide 19: Stable business with resilient and durable cash flows
Confidential - Sensitive Stable business with resilient and durable cash flows 2022 Revenue: INR 26,180 mm Manufacturing Key Brands SIL Manufacturing (General Medicines Unit in Goa & 28% Business) CMO 72% SIL Consumer Local Healthcare manufacturing (Demerged entity) via CMO General Medicines CHC 17
Slide 20: GenMed – Increased focus on growth drivers identified in IFI plan
Confidential - Sensitive GenMed – Increased focus on growth drivers identified in IFI plan Strengthen key strategic therapeutic areas Accelerate Innovation Evolve GTM • Further focus resources on • Expand portfolio through global & local • Improve patient and customer therapeutic areas with leadersh
Slide 21: CHC – Position to create a fast-moving consumer healthcare company
Confidential - Sensitive CHC – Position to create a fast-moving consumer healthcare company Business plan growth levers Upsides beyond plans 50% 35% 15% Accelerate growth Best in class digital / e- § Explore opportunities to commerce capabilities grow inorganically Build consumer centric § Step up e
Slide 22: Proposed demerger benefits
Confidential - Sensitive Proposed demerger benefits Path to unlock significant value creation for shareholders GenMed to focus on its key categories, global and local innovation, GTM & reach expansion Consumer Healthcare to develop fast-moving consumer healthcare capabilities Analyst and investor co
Slide 23: Appendix
04 Appendix
Slide 24: General Medicines is well positioned with leading brands
Confidential - Sensitive General Medicines is well positioned with leading brands #1 #1 #1 #1 Category Diabetes Diabetes CVS CNS n #1 in Value and Volume among basal analogs n Share in the Glimepiride n Clexane #1 player by value n #1 anti epiletic market is 28% over the last 5 years Lantus: top 5 b
Slide 25: Sanofi Consumer Healthcare is a robust platform with leading brands
Confidential - Sensitive Sanofi Consumer Healthcare is a robust platform with leading brands #1 #5 #6 Category Allergy Vitamin D Pain Care n Allegra #1 in allergy orals category since 15 years n DePURA pioneered nano n 41 strips of Combiflam sold technology every second Product n #2 most prescribed
Slide 26: Glossary
Confidential - Sensitive Glossary BSE Bombay Stock Exchange CMO Contract Manufacturing Organization CAGR Compound Annual Growth Rate CHC Consumer Healthcare CNS Central Nervous System CVS Cardio Vascular System GMP Good Manufacturing Practices standards by various agencies GTM Go-to-market HCP Healt